Table 3 Clinical and laboratory parameters in ARF group and non-ARF group

Age

58.3 ± 10.5

58.1 ± 9.6

0.962

Sex

0.671

 Male (%)

5 (71.4)

9 (60)

 Female (%)

2 (28.6)

6 (40)

Drug duration (days)

15.9 ± 7.8

13.0 ± 9.4

0.494

Drug total dose (mg)

4757.1 ± 2345.8

3753.3 ± 2723.9

0.412

WBC (× 10³/uL)

9.4 ± 5.4

5.9 ± 2.0

0.034

CK (U/L)

26,467.8 ± 22,434.3

18,601.6 ± 11,893.8

0.290

LDH (U/L)

2836.0 ± 2497.6

2080.1 ± 712.3

0.282

AST (U/L)

1495.8 ± 718.3

967.3 ± 553.9

0.085

ALT (U/L)

464.9 ± 215.7

350.8 ± 240.8

0.327

Albumin (g/dL)

3.2 ± 0.6

2.7 ± 0.6

0.105

BUN (mg/dL)

56.7 ± 32.3

17.3 ± 6.9

< 0.001

Creatinine (mg/dL)

4.2 ± 2.6

0.8 ± 0.3

< 0.001

Sodium (mmol/L)

131.1 ± 6.5

137.8 ± 5.5

0.020

Potassium (mmol/L)

5.2 ± 0.8

4.3 ± 0.4

0.001

Hospital days

17.6 ± 9.8

22.9 ± 9.4

0.234

 Muscle pain (%)

7 (100)

13 (86.7)

0.545

 Muscle weakness (%)

3 (42.9)

6 (40.0)

1.000

 Oliguria (%)

4 (57.1)

0 (0)

0.005

 Dark urine (%)

2 (28.6)

1 (6.7)

0.227

LC (%)

5 (26.3)

14 (93.3)

0.227

Child-Pugh classification

0.312

 A (%)

0 (0)

3 (21.4)

 B (%)

1 (20.0)

6 (42.9)

 C (%)

4 (80.0)

5 (35.7)

Severe hepatic derangement

4 (80)

5 (35.7)

0.376

Etiology of LC

0.830

 Hepatitis B (%)

3 (60)

9 (64.3)

 Hepatitis C (%)

1 (20)

1 (5.3)

 Alcohol (%)

1 (20)

3 (25.1)

 Cryptogenic (%)

0 (0)

1 (5.3)

Death (%)

4 (57.1)

0 (0)

0.005